In preclinical studies, ISM0900 demonstrates potent and selective inhibition of Lp(a) assembly at nanomolar-level activity (IMAGE)

InSilico Medicine

In preclinical studies, ISM0900 demonstrates potent and selective inhibition of Lp(a) assembly at nanomolar-level activity

Caption

More specifically, ISM0900 achieved an 83.9% reduction in Lp(a), and superior Lp(a) lowering was observed consistently across the study period. At the same dose level, ISM0900 demonstrated superior Lp(a)-lowering efficacy. Also, ISM0900 reached its peak effect by Day 4, signaling an onset time of less than 40% of available clinical-stage candidates.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.